Plain-English translation of NCT05795842 on ClinicalTrials.gov ↗ · Source last updated ·
This trial is testing whether smartwatches—specifically a Moto 360 or Samsung Galaxy Watch 6—can reliably detect atrial fibrillation (an irregular heartbeat that increases stroke risk) by analyzing heart rhythm signals. Researchers will use artificial intelligence to teach the watches to recognize patterns of atrial fibrillation, while comparing the smartwatch data to standard clinical heart monitors you'll also wear. If successful, this technology could help doctors catch irregular heartbeats early in stroke patients, when treatment can prevent future strokes.
Many people over 65 have atrial fibrillation without knowing it, and catching it early with blood-thinning medications can reduce stroke risk by nearly two-thirds. Current monitoring methods are uncomfortable, short-lived, or invasive, so researchers are testing whether everyday smartwatches could provide continuous, passive monitoring that patients actually want to wear.
You likely qualify if…
You likely don't qualify if…
You will wear two devices at the same time: a standard clinical heart monitor (either a patch or a small implanted device your doctor prescribes) and a smartwatch (either a Moto 360 or Samsung Galaxy Watch 6) fitted with special software to continuously record your heart rhythm. The smartwatch will collect data passively in your daily life, while the clinical monitor serves as the accurate reference standard. You'll need to keep both devices on and charged, and continue follow-up care at Emory Stroke Clinic.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States